| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $590,935 ) |
| | 2024 | 2024 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R44DK136390 | A novel peptide assay for hepcidin clinical monitoring | 000 | 2 | NIH | 5/21/2024 | $590,935 |
| | 2024 | 2022 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R44MD016365 | A Rapid Point of Care Test for APOL1 Renal Risk Alleles | 000 | 2 | NIH | 8/27/2024 | $0 |
| | 2024 | 2022 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R44DK118994 | Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients | 000 | 4 | NIH | 9/4/2024 | $0 |
| | 2024 | 2021 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R44AI140931 | Novel assay to monitor Tacrolimus levels at the point of care | 000 | 4 | NIH | 4/24/2024 | $0 |
| | 2024 | 2021 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R44AI148062 | Development of a novel clinical assay for measuring everolimus levels | 000 | 3 | NIH | 2/20/2024 | $0 |
| | 2024 | 2021 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R43AI155250 | Novel clinical assay to rapidly monitor posaconazole levels in plasma | 000 | 1 | NIH | 1/23/2024 | $0 |
| | 2024 | 2020 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R44EB024288 | Point-of-care device to identify patients at risk for preeclampsia | 000 | 5 | NIH | 2/7/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $603,685 ) |
| | 2023 | 2023 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R44DK136390 | A novel peptide assay for hepcidin clinical monitoring | 000 | 1 | NIH | 7/17/2023 | $613,787 |
| | 2023 | 2022 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R44DK118994 | Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients | 000 | 4 | NIH | 8/29/2023 | $0 |
| | 2023 | 2020 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R43HL150911 | Immunoprofiling to develop a novel diagnostic array for cardiac sarcoidosis | 000 | 1 | NIH | 11/23/2022 | $0 |
| | 2023 | 2020 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R44EB024288 | Point-of-care device to identify patients at risk for preeclampsia | 001 | 5 | NIH | 8/11/2023 | $0 |
| | 2023 | 2020 | "AFFINERGY, LLC" | \"104 TW ALEXANDER DRIVE, BLDG. 20 \ | DURHAM | NC | 27709-0002 | DURHAM | USA | R44EB024288 | Point-of-care device to identify patients at risk for preeclampsia | 000 | 5 | NIH | 12/21/2022 | $0 |
| | 2023 | 2018 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R44GM106489 | Novel technologies to remove obscuring blood from fine needle aspiration biopsies | 000 | 4 | NIH | 2/22/2023 | -$10,102 |
|
| Issue Date FY: 2022 ( Subtotal = $1,368,227 ) |
| | 2022 | 2022 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R44DK118994 | Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients | 001 | 4 | NIH | 5/11/2022 | $682,788 |
| | 2022 | 2022 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R44MD016365 | A Rapid Point of Care Test for APOL1 Renal Risk Alleles | 001 | 2 | NIH | 4/30/2022 | $74,138 |
| | 2022 | 2022 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R44MD016365 | A Rapid Point of Care Test for APOL1 Renal Risk Alleles | 000 | 2 | NIH | 2/28/2022 | $667,233 |
| | 2022 | 2021 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R44DK118994 | Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients | 000 | 3 | NIH | 5/10/2022 | $0 |
| | 2022 | 2020 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R43HL150911 | Immunoprofiling to develop a novel diagnostic array for cardiac sarcoidosis | 000 | 1 | NIH | 4/26/2022 | -$55,932 |
| | 2022 | 2020 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R43NS115201 | Development of a peptide-based diagnostic for amyotrophic lateral sclerosis | 000 | 1 | NIH | 7/20/2022 | $0 |
| | 2022 | 2019 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R44DK118994 | Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients | 002 | 1 | NIH | 6/13/2022 | $0 |
| | 2022 | 2019 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R44HD090786 | Novel technologies for detection of podocytes from preeclamptic patients | 000 | 4 | NIH | 2/28/2022 | $0 |
| | 2022 | 2019 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R43HL149446 | Development of a multiplex point-of-care assay to identify patients with Venous Thromboembolism | 000 | 1 | NIH | 2/1/2022 | $0 |
| | 2022 | 2018 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R44AR066997 | Stem cell-binding peptides for rapid fixation of total hip replacements | 000 | 3 | NIH | 12/22/2021 | $0 |
| | 2022 | 2016 | AFFINERGY, LLC | 104 TW ALEXANDER DRIVE, BLDG. 20 | DURHAM | NC | 27709-0002 | DURHAM | USA | R43CA206675 | Peptide-based slides for improving the diagnostic quality of sputum specimens | 000 | 1 | NIH | 10/1/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $3,021,386 ) |
| | 2021 | 2021 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R43AI155250 | Novel clinical assay to rapidly monitor posaconazole levels in plasma | 000 | 1 | NIH | 4/2/2021 | $294,541 |
| | 2021 | 2021 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R44AI140931 | Novel assay to monitor Tacrolimus levels at the point of care | 000 | 4 | NIH | 6/24/2021 | $735,018 |
| | 2021 | 2021 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R44DK118994 | Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients | 000 | 3 | NIH | 4/27/2021 | $679,410 |
| | 2021 | 2021 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R44AI148062 | Development of a novel clinical assay for measuring everolimus levels | 000 | 3 | NIH | 5/3/2021 | $648,895 |
| | 2021 | 2021 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R44MD016365 | A Rapid Point of Care Test for APOL1 Renal Risk Alleles | 000 | 1 | NIH | 6/30/2021 | $685,035 |
| | 2021 | 2018 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R43AI138631 | Autoantibody profiling to develop a novel diagnostic array for systemic sclerosis | 000 | 1 | NIH | 12/21/2020 | $0 |
| | 2021 | 2018 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R44GM106489 | Novel technologies to remove obscuring blood from fine needle aspiration biopsies | 000 | 4 | NIH | 12/9/2020 | -$21,513 |
|
| Issue Date FY: 2020 ( Subtotal = $3,343,663 ) |
| | 2020 | 2020 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R43HL150911 | Immunoprofiling to develop a novel diagnostic array for cardiac sarcoidosis | 000 | 1 | NIH | 6/16/2020 | $299,802 |
| | 2020 | 2020 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R43NS115201 | Development of a peptide-based diagnostic for amyotrophic lateral sclerosis | 000 | 1 | NIH | 1/4/2020 | $299,778 |
| | 2020 | 2020 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R44EB024288 | Point-of-care device to identify patients at risk for preeclampsia | 000 | 5 | NIH | 9/15/2020 | $702,122 |
| | 2020 | 2020 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R44DK118994 | Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients | 000 | 2 | NIH | 5/12/2020 | $590,249 |
| | 2020 | 2020 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R44AI140931 | Novel assay to monitor Tacrolimus levels at the point of care | 000 | 3 | NIH | 6/26/2020 | $734,099 |
| | 2020 | 2020 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R44AI148062 | Development of a novel clinical assay for measuring everolimus levels | 000 | 2 | NIH | 4/21/2020 | $717,613 |
| | 2020 | 2018 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R43MD013402 | A novel clinical assay for detection of APOL1 renal risk alleles | 000 | 1 | NIH | 2/9/2020 | $0 |
| | 2020 | 2018 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R44AR066997 | Stem cell-binding peptides for rapid fixation of total hip replacements | 000 | 3 | NIH | 6/22/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $3,793,794 ) (Continued on the next page) |
| | 2019 | 2019 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R44EB024288 | Point-of-care device to identify patients at risk for preeclampsia | 000 | 4 | NIH | 7/29/2019 | $736,241 |
| | 2019 | 2019 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R43HL149446 | Development of a multiplex point-of-care assay to identify patients with Venous Thromboembolism | 000 | 1 | NIH | 9/4/2019 | $297,440 |
| | 2019 | 2019 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R43DA046998 | Development of a multiplex peptide array to identify patients with an autoantibody signature for chronic pain | 000 | 1 | NIH | 2/28/2019 | $320,058 |
| | 2019 | 2019 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R44DK118994 | Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients | 000 | 1 | NIH | 4/29/2019 | $283,225 |
| | 2019 | 2019 | AFFINERGY, LLC | 601 KEYSTONE PARK DR STE 100 | MORRISVILLE | NC | 27560-6363 | WAKE | USA | R44AI140931 | Novel assay to monitor Tacrolimus levels at the point of care | 001 | 2 | NIH | 7/29/2019 | $759,336 |
|
